B Cell Numbers Predict Humoral and Cellular Response Upon SARS–CoV‐2 Vaccination Among Patients Treated With Rituximab

OBJECTIVE: Patients with autoimmune inflammatory rheumatic diseases receiving rituximab (RTX) therapy are at higher risk of poor COVID‐19 outcomes and show substantially impaired humoral immune response to anti–SARS–CoV‐2 vaccine. However, the complex relationship between antigen‐specific B cells an...

Descripción completa

Detalles Bibliográficos
Autores principales: Stefanski, Ana‐Luisa, Rincon‐Arevalo, Hector, Schrezenmeier, Eva, Karberg, Kirsten, Szelinski, Franziska, Ritter, Jacob, Jahrsdörfer, Bernd, Schrezenmeier, Hubert, Ludwig, Carolin, Sattler, Arne, Kotsch, Katja, Chen, Yidan, Claußnitzer, Anne, Haibel, Hildrun, Proft, Fabian, Guerra, Gabriela, Durek, Pawel, Heinrich, Frederik, Ferreira‐Gomes, Marta, Burmester, Gerd R., Radbruch, Andreas, Mashreghi, Mir‐Farzin, Lino, Andreia C., Dörner, Thomas
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Wiley Periodicals, Inc. 2022
Materias:
COVID‐19
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9011692/
https://www.ncbi.nlm.nih.gov/pubmed/34962360
http://dx.doi.org/10.1002/art.42060

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9011692/
https://www.ncbi.nlm.nih.gov/pubmed/34962360
http://dx.doi.org/10.1002/art.42060

Ejemplares similares